February 7, 2025 07:18 AM ESTUpdated 08:53 AM
R&D

No­vo Nordisk takes aim at Roche in he­mo­phil­ia A, but is way be­hind

Elizabeth Cairns

Senior biopharma journalist

No­vo Nordisk said Fri­day that its he­mo­phil­ia A pre­ven­tive Mim8 was ef­fec­tive in its pe­di­atric tri­al, open­ing it up to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Less than two years af­ter block­buster IPO, Ace­lyrin merges with Alu­mis to com­bine cash, as­sets

Long­time San­doz ex­ec an­nounces re­tire­ment; Lil­ly ap­points head of In­dia

Sion­na inks $191M IPO for cys­tic fi­bro­sis pipeline as Aard­vark eyes $89M for its own list­ing

Bris­tol My­ers prunes pipeline amid new round of cost cuts

Pfiz­er hires No­var­tis on­col­o­gy ex­ec to steer its can­cer am­bi­tions

Bris­tol My­ers launch­es fresh round of ma­jor cost cuts in bid to get ahead of patent cliff

A service from the Financial Times